A Community-transmitted Case of Severe Acute Respiratory Distress Syndrome (SARS) Due to SARS-CoV-2 in the United States

Clinical Infectious Diseases

Volumn 71, Issue 16, 2020, Pages 2222-2226

  Sanville, Bradley ^a   Corbett, Rebecca ^a   Pidcock, Wesley ^a   Hardin, Kaitlyn ^a   Sebat, Christian ^a   Nguyen, Minh Vu ^a   Thompson, George R ^a   Haczku, Angela ^a   Schivo, Michael ^a   Cohen, Stuart ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

community transmission; COVID 19; index case; novel coronavirus; SARS CoV 2

Indexed keywords

AZITHROMYCIN; CISATRACURIUM; FENTANYL; LINEZOLID; NORADRENALIN; PIPERACILLIN PLUS TAZOBACTAM; PROPOFOL; REMDESIVIR; VASOPRESSIN; ADENOSINE PHOSPHATE; ALANINE; ANTIVIRUS AGENT;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BLOOD BIOCHEMISTRY; BRONCHOGRAPHY; BRONCHOSCOPY; CASE REPORT; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; COMPUTER ASSISTED TOMOGRAPHY; CORONAVIRUS DISEASE 2019; COVID-19 TESTING; CRYSTALLOID; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; ENDOTRACHEAL INTUBATION; EXTRACORPOREAL OXYGENATION; FEMALE; FLU LIKE SYNDROME; FLUID RESUSCITATION; FOLLOW UP; HEALTH CARE POLICY; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOXEMIA; OXYGEN THERAPY; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; SCREENING TEST; SEPTIC SHOCK; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; THORAX RADIOGRAPHY; TRAVEL; UNITED STATES; VIRUS TRANSMISSION; COMMUNITY ACQUIRED INFECTION; COMPLICATION; DIAGNOSTIC IMAGING; EPIDEMIOLOGY; MIDDLE AGED; RESPIRATORY DISTRESS SYNDROME; RISK FACTOR; THORAX; TREATMENT OUTCOME; VIROLOGY; X-RAY COMPUTED TOMOGRAPHY;

ADENOSINE MONOPHOSPHATE; ADULT; ALANINE; ANTIVIRAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; COVID-19; FEMALE; HUMANS; MIDDLE AGED; RESPIRATORY DISTRESS SYNDROME; RISK FACTORS; SHOCK, SEPTIC; THORAX; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; UNITED STATES;

EID: 85083224539     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciaa347     Document Type: Article

References (19)

1. 1. World Health Organization. Emergencies preparedness, response. Pneumonia of unknown cause-China. 2020. Available at: https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/. Accessed 21 March 2020.
2. 2. Centers for Disease Control and Prevention. Update and interim guidance on outbreak of 2019 novel coronavirus (2019-nCoV). 2020. Available at: https://emergency.cdc.gov/han/han00427.asp. Accessed 21 March 2020.
3. 3. Liu YC, Liao CH, Chang CF, Chou CC, Lin YR. A locally transmitted case of SARS-CoV-2 infection in Taiwan. N Engl J Med 2020; 382:1070-2.
4. 4. Centers for Disease Control and Prevention. Evaluating and reporting persons under investigation (PUI). Coronavirus disease 2019 (COVID-19). 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria. html. Accessed 21 March 2020.
5. 5. Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 novel corona-virus (2019-nCoV). Radiology 2020; 295:202-7.
6. 6. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020. doi:10.1056/NEJMoa2002032.
7. 7. Pan F, Ye T, Sun P, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology 2020; 200370. doi:10.1148/radiol.2020200370.
8. 8. Bernheim A, Mei X, Huang M, et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology 2020; 200463. doi:10.1148/radiol.2020200463.
9. 9. Wu Z, McGoogan JM. Characteristics of and important lessons from the corona-virus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020. doi:10.1001/jama.2020.2648.
10. 10. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol 2020. doi:10.1002/jmv.25748.
11. 11. Khot WY, Nadkar MY. The 2019 novel coronavirus outbreak-a global threat. J Assoc Physicians India 2020; 68:67-71.
12. 12. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507-13.
13. 13. de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA 2020; 117:6771-6.
14. 14. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses-drug discovery and therapeutic options. Nat Rev Drug Discov 2016; 15:327-47.
15. 15. Murphy BG, Perron M, Murakami E, et al. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Vet Microbiol 2018; 219:226-33.
16. 16. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel co-ronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill 2020; 25. doi:10.2807/1560-7917. ES.2020.25.5.2000062.
17. 17. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020; 104:246-51.
18. 18. Fauci AS, Lane HC, Redfield RR. COVID-19-navigating the uncharted. N Engl J Med 2020; 382:1268-9.
19. 19. Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020. doi:10.1001/jama.2020.2565.